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成像和肿瘤光热治疗。我们将上述纳米颗粒 IHANPT 通过尾静脉注射到 SCC7
荷瘤小鼠体内，并在肿瘤部位观察到明显的光声信号。随后，我们使用低功率的














































Cancer has become a major problem in the field of human health. Early diagnosis 
and imaging guided therapy are significant for cancer treatment. Nanomedicine 
including but not limited to liposomes, inorganic nanoparticles, polymer based 
micelles have been widely used as multifunctional drug carriers for cancer theranostic. 
An ideal nanosystem should have the following characteristics (1) it should allow 
early visualization of tumors, (2) it should efficiently deliver drugs to the tumor sites, 
(3) it is possible to monitor the distribution of the theranostic agent in vivo,  (4) it 
could provide optimized therapeutic strategy under the guidance of imaging in order 
to reduce side effects. Nanomaterials with high cancer theranostic effectiveness and 
clinical translational potential are of high desire.  
In the second chapter, we introduced a novel nanosystem by coating SWCNTs with 
indocyanine green (ICG) coupled hyaluronic acid nanoparticle (HANPs) for enhanced 
PDT/PTT cancer treatment under photoacoustic (PA) imaging guidance. In our system, 
both ICG and SWCNTs have strong near infrared (NIR) absorption and high 
photothermal conversion efficiency, and are widely used as PA and photothermal 
agents. HA could actively target to cancer cells overexpressed with CD44, and thus 
greatly improve the tumor accumulation of the nanosystem. We intravenously (IV) 
injected IHANPT into xx mice and monitored their tumor accumulation via PA 
imaging. A NIR laser (808 nm, 0.8 W/cm
2
) was applied to irradiate the tumor area for 
photothermal therapy. We found that under the guidance of PA imaging, the 
IHANPT-mediated phototherapy could efficiently ablate the tumor without any tumor 
recurrence.  
Photodynamic therapy is another well-known therapeutic strategy. Upon the laser 
irradiation, the photosensitizer produce reactive oxygen species (ROS) which could 
kill the tumor cells. The therapeutic efficiency is highly related with the oxygen level. 
In order to improve the hypoxia state of the tumor microenvironment and thus, 
improve the photodynamic therapy effect, we designed an oxygen-generating PDT 
nanocomplex by encapsulating a manganese dioxide nanoparticle (MnO2 NP) into an 
ICG modified HANPs. The tumor accumulation of the ICG-HANP/MnO2 (IHM) 















intravenous administration into the SCC7 tumor-bearing mouse model. In addition, 
due to the high reactivity of MnO2 NP to H2O2, the oxygen content in the tumor is 
elevated to 2.25 ± 0.07 times compared to that without IHM treatment as ultrasound 
imaging confirmed. After laser irradiation, significant tumor growth inhibition was 
observed in the IHM-treated group compared to the ICG-HANP-treated group. 
Further details can be found in the third chapter. 
In summary, this thesis described two HA based multifunctional nanomaterials 
for theranostic application. We believe that our design will benefit the cancer 
theranostic and have clinical translational potential.  
Keywords: Hyaluronic Acid Nanoparticles; ICG; SWCNT Nanoparticles; Manganese 
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第一章 绪 论 
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Figure 1.1 Lipid and polymer-based nanoparticulate systems used in the field of drug delivery and 
active targeting. 
1.2.1 透明质酸纳米颗粒 
































作用，可以大大提高肿瘤对 HANP 纳米药物的摄取[5]。（3）HANP 的体内可降解。
HANP 可以被肿瘤细胞中透明质酸酶（主要是透明质酸酶 1和 2）分解，进而可
以迅速将药物完全释放[6]。（4）HANP 为药物提供缓释作用，对治疗药物的水溶
性也无严格限制。这种药物含有亲水外壳可逃避单核巨噬细胞的吞噬，延长其血




图 1.2 透明质酸纳米颗粒的细胞摄取通路和药物释放行为。 
Figure 1.2 Hyaluronic acid nanoparticle of hypothetical cellular uptake pathways and 
subcellular drug release behaviors. 
1.2.2 聚乙二醇 




定性较高、血液循环时间较长等诸多优势。Duong 等以 PLGA-PEG 为载体材料
制备了同时载有 DOX 和 PTX 的多功能化 PMs，并用穿膜肽 TAT 和靶向受体叶
酸对其表面进行修饰，增加了体系的治疗效果。 
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